PEGylated Proteins Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-31　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.2 Bn
2033 年預估規模: USD 4.7 Bn
年複合成長率 CAGR: 11.6%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-31頁數 152報告編號 CMI5354

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

PEGylated Proteins Market, By Type (Consumables and Services), By Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII and Other), By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder and Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations and Academic Research Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals. Due to its claimed silent qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes. Market Dynamics Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei. Key features of the study • This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global PEGylated proteins market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market Market Segmentation • By Type o Consumables o Services • By Protein o Colony-stimulating factor o Interferons o Erythropoietin o Recombinant factor VII o Other • By Application o Cancer o Autoimmune Disease o Hepatitis o Multiple Sclerosis o Hemophilia o Gastrointestinal Disorder o Others • By End User o Pharmaceutical and Biotechnology Companies o Contract Research Organizations o Academic Research Institutes • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Biogen Inc o Pfizer Inc o UCB S.A. o Leadiant Biosciences, Inc. o Amgen Inc. o Thermo Fisher Scientific Inc. o Horizon Therapeutics Plc. o Novo Nordisk A/S o Hoffmann-La Roche AG o Bayer AG o BioMarin o RedHill Biopharma Ltd.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Protein  Market Snapshot, By Application  Market Snapshot, By End User  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Recent Developments o Acquisitions and Partnerships Scenario o Technology Overview o Regulatory Scenario o Pipeline Analysis o PEST Analysis 4. Global PEGylated Proteins Market, By Type, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Consumables  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)  Others o Services  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global PEGylated Proteins Market, By Protein, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Colony Stimulating Factor  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)  Others o Interferon  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Erythropoietin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Recombinant Factor VII  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global PEGylated Proteins Market, By Application, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Cancer  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Autoimmune Disease  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Hepatitis  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Multiple Sclerosis  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Hemophilia  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Gastrointestinal Disorder  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global PEGylated Proteins Market, By End User, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Pharmaceutical and Biotechnology Companies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Contract Research Organizations  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Academic Research Institutes  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global PEGylated Proteins Market, By Region, 2026 – 2033, (USD Bn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2021-2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033, (USD Bn) o North Africa o Central Africa o South Africa 9. Competitive Landscape o Biogen Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o UCB S.A.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Leadiant Biosciences, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Amgen Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Thermo Fisher Scientific Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Horizon Therapeutics Plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Novo Nordisk A/S  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o F. Hoffmann-La Roche AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Bayer AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o BioMarin  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o RedHill Biopharma Ltd  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 10. Section o Research Methodology o About Us

提及公司

Biogen IncPfizer IncUCB S.A.Leadiant Biosciences, Inc.Amgen Inc.Thermo Fisher Scientific Inc.Horizon Therapeutics Plc.Novo Nordisk A/SHoffmann-La Roche AGBayer AGBioMarinRedHill Biopharma Ltd.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們